[go: up one dir, main page]

ATE260971T1 - Verfahren zur in vitro kultivierung dendritischer vorläuferzellen und deren verwendung zur immunogen herstellung - Google Patents

Verfahren zur in vitro kultivierung dendritischer vorläuferzellen und deren verwendung zur immunogen herstellung

Info

Publication number
ATE260971T1
ATE260971T1 AT93911581T AT93911581T ATE260971T1 AT E260971 T1 ATE260971 T1 AT E260971T1 AT 93911581 T AT93911581 T AT 93911581T AT 93911581 T AT93911581 T AT 93911581T AT E260971 T1 ATE260971 T1 AT E260971T1
Authority
AT
Austria
Prior art keywords
antigens
antigen
dendritic
producing
dendritic cell
Prior art date
Application number
AT93911581T
Other languages
English (en)
Inventor
Ralph M Steinman
Kayo Inaba
Gerold Schuler
Original Assignee
Univ Rockefeller
Merix Bioscience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Rockefeller, Merix Bioscience Inc filed Critical Univ Rockefeller
Priority claimed from PCT/US1993/003141 external-priority patent/WO1993020185A1/en
Application granted granted Critical
Publication of ATE260971T1 publication Critical patent/ATE260971T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/45—Bacterial antigens
    • A61K40/4528—Bacillus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/25—Tumour necrosing factors [TNF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AT93911581T 1992-04-01 1993-04-01 Verfahren zur in vitro kultivierung dendritischer vorläuferzellen und deren verwendung zur immunogen herstellung ATE260971T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US86161292A 1992-04-01 1992-04-01
US98135792A 1992-11-25 1992-11-25
US4067793A 1993-03-31 1993-03-31
PCT/US1993/003141 WO1993020185A1 (en) 1992-04-01 1993-04-01 Method for in vitro proliferation of dendritic cell precursors and their use to produce immunogens

Publications (1)

Publication Number Publication Date
ATE260971T1 true ATE260971T1 (de) 2004-03-15

Family

ID=27365767

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93911581T ATE260971T1 (de) 1992-04-01 1993-04-01 Verfahren zur in vitro kultivierung dendritischer vorläuferzellen und deren verwendung zur immunogen herstellung

Country Status (9)

Country Link
US (5) US5994126A (de)
EP (1) EP0633929B1 (de)
JP (1) JP3649335B2 (de)
AT (1) ATE260971T1 (de)
CA (1) CA2133409C (de)
DE (1) DE69333433T2 (de)
DK (1) DK0633929T3 (de)
ES (1) ES2215991T3 (de)
PT (1) PT633929E (de)

Families Citing this family (174)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE260971T1 (de) 1992-04-01 2004-03-15 Univ Rockefeller Verfahren zur in vitro kultivierung dendritischer vorläuferzellen und deren verwendung zur immunogen herstellung
US20020085993A1 (en) * 1992-11-25 2002-07-04 Ralph M. Steinman Method for in vitro proliferation of dendritic cell precursors and their use to produce immunogens
US6300090B1 (en) * 1994-07-29 2001-10-09 The Rockefeller University Methods of use of viral vectors to deliver antigen to dendritic cells
US5871728A (en) * 1995-03-31 1999-02-16 University Of Pittsburgh Method of regulating dendritic cell maturation
US20010012632A1 (en) * 1995-03-31 2001-08-09 Muriel Moser Dendritic-like cell/tumor cell hybrids and hybridomas for inducing an anti-tumor response
US20020182730A1 (en) * 1995-07-26 2002-12-05 Micheal L. Gruenberg Autologous immune cell therapy: cell compositions, methods and applications to treatment of human disease
US7150992B1 (en) * 1995-10-04 2006-12-19 Innunex Corporation Methods of preparing dendritic cells with flt3-ligand and antigen
US6080409A (en) * 1995-12-28 2000-06-27 Dendreon Corporation Immunostimulatory method
US7659119B2 (en) * 1996-02-12 2010-02-09 Argos Therapeutics, Inc. Method and compositions for obtaining mature dendritic cells
EP0808897A1 (de) * 1996-05-21 1997-11-26 I.D.M. Immuno-Designed Molecules Antigenpräsentierende Zellen, ein Verfahren zur deren Herstellung und deren Verwendung als zelluläre Impfstoffen
AU705647B2 (en) * 1996-07-10 1999-05-27 Immunex Corporation Method of activating dendritic cells
US6458585B1 (en) 1996-08-14 2002-10-01 Nexell Therapeutics Inc. Cytokine-free culture of dendritic cells
US6251665B1 (en) 1997-02-07 2001-06-26 Cem Cezayirli Directed maturation of stem cells and production of programmable antigen presenting dentritic cells therefrom
US6977073B1 (en) 1997-02-07 2005-12-20 Cem Cezayirli Method for stimulating an immune response
US20040110283A1 (en) * 1997-02-27 2004-06-10 University Of Pittsburgh Of The Commonwealth System Of Higher Education Induction of tumor and viral immunity using antigen presenting cell co-culture products and fusion products
US20050169898A1 (en) * 1997-04-15 2005-08-04 Jianlin Gong Cell fusions and methods of making and using the same
EP1007720B1 (de) 1997-04-15 2008-03-05 Dana Farber Cancer Institute, Inc. Dendritische zellhybride
AU7499498A (en) * 1997-05-21 1998-12-11 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Methods and compositions for making dendritic cells from expanded populations ofmonocytes and for activating t cells
ATE428769T1 (de) 1997-10-27 2009-05-15 Univ Rockefeller Methode und zusammensetzung zur herstellung von reifen dendritischen zellen
ES2590912T3 (es) 1997-12-08 2016-11-24 Merck Patent Gmbh Proteínas de fusión heterodiméricas útiles para inmunoterapia dirigida y estimulación general del sistema inmunitario
AU2872199A (en) * 1998-02-20 1999-09-06 Rockefeller University, The Apoptotic cell-mediated antigen presentation to dendritic cells
US20020034819A1 (en) * 1998-02-23 2002-03-21 Alan K. Smith Human lineage committed cell composition with enhanced proliferative potential, biological effector function, or both; methods for obtaining same; and their uses
EP1068296B1 (de) 1998-03-31 2011-08-10 Geron Corporation Zusammensetzungen zur auslösung einer immunantwort gegen ein telomerase antigen
US7402307B2 (en) 1998-03-31 2008-07-22 Geron Corporation Method for identifying and killing cancer cells
US6835550B1 (en) * 1998-04-15 2004-12-28 Genencor International, Inc. Mutant proteins having lower allergenic response in humans and methods for constructing, identifying and producing such proteins
US6936249B1 (en) * 1998-04-15 2005-08-30 Genencor International, Inc. Proteins producing an altered immunogenic response and methods of making and using the same
US6921751B1 (en) * 1998-05-20 2005-07-26 Erasmus Universiteit Rotterdam Immunoregulator
EP1138692A1 (de) * 2000-03-29 2001-10-04 Erasmus Universiteit Rotterdam Fragmente des menschlichen Choriongonadotropins als Immunoregulatoren
US20040202645A1 (en) * 2003-04-08 2004-10-14 Khan Nisar Ahmed Administration of gene-regulatory peptides
US6844315B2 (en) 1998-05-20 2005-01-18 Erasmus Universiteit Rotterdam Immunoregulator
US20030220258A1 (en) * 2001-12-21 2003-11-27 Robbert Benner Treatment of ischemic events
US20050227925A1 (en) * 2004-04-08 2005-10-13 Robbert Benner Compositions capable of reducing elevated blood urea concentration
US8680059B2 (en) * 1998-05-20 2014-03-25 Biotempt B.V. Oligopeptide acetate and formulations thereof
US7521197B2 (en) * 1998-06-05 2009-04-21 Alexis Biotech Limited Method for producing cytotoxic T-cells
US20020051783A1 (en) * 1998-06-05 2002-05-02 Savage Philip Michael Method for producing or enhancing a T-cell response against a target cell using a complex comprising an HLA class I molecule and an attaching means
US7264965B2 (en) * 1998-06-05 2007-09-04 Alexis Biotech Limited Method for producing or enhancing a T-cell response against a target cell using a complex comprising an HLA class I molecule and an attaching means
US6558951B1 (en) * 1999-02-11 2003-05-06 3M Innovative Properties Company Maturation of dendritic cells with immune response modifying compounds
EP1165144A2 (de) * 1999-03-15 2002-01-02 Introgen Therapeutics, Inc. Mit einem eigengen-wildtyp transduzierte dendritische zellen lösen starke antitumor immunantwort aus
US20020090381A1 (en) * 1999-04-09 2002-07-11 H. Kim Bottomly System for controlling immune system response to antigen
US6977245B2 (en) * 1999-04-12 2005-12-20 The United States Of America As Represented By The Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
EP1175497B1 (de) 1999-04-14 2010-04-07 Novartis Vaccines and Diagnostics, Inc. Zusammensetzungen und verfahren zur auslösung einer immunantwort auf basis alphavirus-vektoren-systeme
WO2000067761A1 (en) * 1999-05-06 2000-11-16 Wake Forest University Compositions and methods for identifying antigens which elicit an immune response
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
US7713739B1 (en) 2000-11-17 2010-05-11 Novartis Vaccines And Diagnostics, Inc. Microparticle-based transfection and activation of dendritic cells
JP4793971B2 (ja) 1999-08-09 2011-10-12 メルク パテント ゲーエムベーハー 複合サイトカイン−抗体複合体
US7005131B1 (en) 1999-08-13 2006-02-28 The Rockefeller University Protective antigen of Epstein Barr Virus
WO2001016343A1 (en) 1999-08-31 2001-03-08 The University Of North Carolina At Chapel Hill Antibody dependent enhancement (ade) of alphavirus infection
DK1224264T3 (da) 1999-10-15 2010-05-10 Baylor Res Inst Anvendelse af allogene cellelinjer til at belaste antigenpræsenterende celler til at fremkomme med immunresponser
US20030077263A1 (en) * 1999-10-29 2003-04-24 Immunex Corporation Method of activating dendritic cells
EP1228214A2 (de) 1999-11-12 2002-08-07 MERCK PATENT GmbH Erythropoietinformen mit verbesserten eigenschaften
US7030228B1 (en) 1999-11-15 2006-04-18 Miltenyi Biotec Gmbh Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby
AU3279301A (en) * 2000-01-11 2001-07-24 Maxygen, Inc. Monocyte-derived dendritic cell subsets
EP1322655B1 (de) * 2000-01-14 2007-11-14 The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services Oligodeoxynukleotide und ihre verwendung zur induktion einer immunreaktion
ATE336514T1 (de) 2000-02-11 2006-09-15 Merck Patent Gmbh Steigerung der zirkulierenden halbwertzeit von auf antikörpern basierenden fusionsproteinen
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
JP2003523398A (ja) 2000-02-24 2003-08-05 ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ 樹状細胞のインビボ活性化によるアジュバント治療
US7541184B2 (en) 2000-02-24 2009-06-02 Invitrogen Corporation Activation and expansion of cells
WO2001062092A1 (en) * 2000-02-25 2001-08-30 Thomas Jefferson University Formulations and methods for using the same to elicit an immune response
US7358330B2 (en) * 2001-03-29 2008-04-15 Biotempt B.V. Immunoregulatory compositions
EP1300418A1 (de) * 2001-10-04 2003-04-09 Erasmus Universiteit Rotterdam Genregulation durch Oligopeptide
US7361329B2 (en) * 2000-04-21 2008-04-22 Chemocentryx, Inc. Compositions for inducing an immune response
CA2407104A1 (en) * 2000-05-12 2001-11-22 Northwest Biotherapeutics, Inc. Method to increase class i presentation of exogenous antigens by human dendritic cells
RU2272644C2 (ru) * 2000-06-29 2006-03-27 Мерк Патент Гмбх Усиление иммунной реакции, медиатором которой является слитый протеин антитело-цитокин, при помощи комбинированного лечения агентами, увеличивающими поглощение иммуноцитокина
AU2524502A (en) * 2000-10-13 2002-04-22 Richard Boyd Improvement of graft acceptance through manipulation of thymic regeneration
US6892140B1 (en) * 2000-11-27 2005-05-10 Enteron, Inc. Immunogenic cancer peptides and uses thereof
US20020094545A1 (en) * 2000-11-30 2002-07-18 Harris Paul E. Growth of human dendritic cells for cancer immunotherapy in closed system using microcarrier beads
MXPA03005373A (es) * 2000-12-13 2004-03-26 Inmunex Corp Metodo para generar lineas celulares dentriticas inmortales.
US20030027334A1 (en) * 2000-12-13 2003-02-06 Fitzpatrick David R. Method for generating immortal dendritic cell lines
DK1366067T3 (da) 2001-03-07 2012-10-22 Merck Patent Gmbh Ekspressionsteknologi for proteiner indeholdende en hybrid isotype-antistof-enhed
FR2821947B1 (fr) * 2001-03-12 2003-05-16 Canon Kk Procede et dispositif de validation de parametres definissant une image
US20020131953A1 (en) * 2001-03-14 2002-09-19 Ut Southwestern Medical Center In situ langerhans cell vaccine
AU2002257064A1 (en) * 2001-03-19 2002-10-03 Cellular Genomics Inc. Methods for isolating proteins expressed by dendritic cells
US6992174B2 (en) 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
AU2002249531A1 (en) * 2001-04-02 2002-10-28 Alimentary Health Limited Immunotherapy based on dendritic cells
US20020193295A1 (en) * 2001-05-04 2002-12-19 Emanuel Calenoff Immunogenic peptides and uses thereof
US20030082806A1 (en) * 2001-04-27 2003-05-01 Xcyte Therapies, Inc. Maturation of antigen-presenting cells using activated T cells
KR20020083634A (ko) * 2001-04-27 2002-11-04 크레아젠 주식회사 수지상 세포를 포함하는 자가면역 질환의 치료용 약제학적조성물 및 이를 이용한 치료방법
US6969517B2 (en) * 2001-05-03 2005-11-29 Emd Lexigen Research Center Corp. Recombinant tumor specific antibody and use thereof
WO2003010292A2 (en) * 2001-07-25 2003-02-06 Northwest Biotherapeutics, Inc. Methods and apparatus for enrichment and culture of monocytic dendritic cell precursors
US7666674B2 (en) 2001-07-27 2010-02-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo
US7354909B2 (en) 2001-08-14 2008-04-08 The United States Of America As Represented By Secretary Of The Department Of Health And Human Services Method for rapid generation of mature dendritic cells
US20030134415A1 (en) * 2001-09-19 2003-07-17 Gruenberg Micheal L. Th1 cell adoptive immunotherapy
US20030134341A1 (en) * 2001-09-19 2003-07-17 Medcell Biologics, Llc. Th1 cell adoptive immunotherapy
US20030220259A1 (en) * 2001-12-21 2003-11-27 Robbert Benner Treatment of neurological disorders
US20030215460A1 (en) * 2002-05-07 2003-11-20 Schall Thomas J. Methods and compositions for inducing an immune response
US20030096260A1 (en) * 2001-10-09 2003-05-22 Zhenhua Miao Compositions useful as ligands for the formyl peptide receptor like 1 receptor and methods of use thereof
BR0214650A (pt) 2001-12-04 2005-05-03 Merck Patent Gmbh Imunocitoquinas com seletividade modulada
US8466116B2 (en) 2001-12-20 2013-06-18 The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of CpG oligodeoxynucleotides to induce epithelial cell growth
AU2002366710A1 (en) 2001-12-20 2003-07-09 The Government Of The United States Of America As Represented By The Secretary Of The Department Of USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS
US20030224995A1 (en) * 2001-12-21 2003-12-04 Khan Nisar Ahmed Treatment of burns
US20040013661A1 (en) * 2001-12-21 2004-01-22 Gert Wensvoort Stratification
US20030220261A1 (en) * 2001-12-21 2003-11-27 Khan Nisar Ahmed Treatment of iatrogenic disease
US20030220257A1 (en) * 2001-12-21 2003-11-27 Robbert Benner Treatment of trauma
US7786084B2 (en) * 2001-12-21 2010-08-31 Biotempt B.V. Treatment of burns
US20030220260A1 (en) * 2001-12-21 2003-11-27 Khan Nisar Ahmed Peptide compositions
US20080318871A1 (en) * 2001-12-21 2008-12-25 Khan Nisar A Treatment of neurological disorders
US7560433B2 (en) * 2001-12-21 2009-07-14 Biotempt B.V. Treatment of multiple sclerosis (MS)
US7501391B2 (en) * 2001-12-21 2009-03-10 Biotempt B.V. Treatment of transplant survival
US20080242837A1 (en) * 2001-12-21 2008-10-02 Khan Nisar A Peptide compositions
US20040230380A1 (en) * 2002-01-04 2004-11-18 Xencor Novel proteins with altered immunogenicity
US20030149646A1 (en) * 2002-02-01 2003-08-07 Ubs Painewebber Inc. Method and system for providing an aggregated stock options report
US20030175272A1 (en) * 2002-03-07 2003-09-18 Medcell Biologics, Inc. Re-activated T-cells for adoptive immunotherapy
US7060494B2 (en) * 2002-04-09 2006-06-13 Reliance Life Sciences Pvt. Ltd. Growth of human Mesenchymal Stem Cells (hMSC) using umbilical cord blood serum and the method for the preparation thereof
US7763251B2 (en) * 2002-04-12 2010-07-27 Medical College Of Georgia Research Institute, Inc. Kits to assess the risk of tumor progression
JP2005524412A (ja) * 2002-05-08 2005-08-18 ノースウエスト バイオセラピューティクス， インコーポレイティド 抗原提示細胞のための品質アッセイ
US7332158B2 (en) * 2002-05-29 2008-02-19 Demao Yang Compositions and treatments for myelosuppression by ex vivo activated immune cells
US7048922B2 (en) * 2002-05-29 2006-05-23 Demao Yang Stimulation of hematopoiesis by ex vivo activated immune cells
CA2388441A1 (en) * 2002-06-10 2003-12-10 Wei-Ping Min Immunomodulation using rna interference
US7465448B2 (en) * 2002-09-11 2008-12-16 Medical College Of Georgia Research Institute, Inc. Chemokine receptor antagonists as therapeutic agents
US8263091B2 (en) 2002-09-18 2012-09-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides
EP1576188B1 (de) 2002-11-21 2008-10-15 Epicentre Technologies Verfahren zur verwendung von riboprimern zur strangverdrängungsreplikation von zielsequenzen
US20060057120A1 (en) 2002-12-06 2006-03-16 Northwest Biotherapeutics Inc. Administration of dendritic cells partially matured in vitro for the treatment of tumors
ATE471946T1 (de) 2002-12-17 2010-07-15 Merck Patent Gmbh Humanisierter antikörper (h14.18) des maus antikörpers 14.18, der gd2 bindet und seine fusion mit il-2
CA2513029A1 (en) * 2003-01-16 2004-08-05 John M. Brittingham Intradermal cellular delivery using narrow gauge micro-cannula
US20040197903A1 (en) * 2003-01-31 2004-10-07 Northwest Biotherapeutics, Inc. Method for induction of proliferation of natural killer cells by dendritic cells cultured with GM-CSF and IL-15
CN1761744A (zh) * 2003-02-10 2006-04-19 西北生物治疗药物公司 培养的cd14+抗原呈递细胞
US20060134067A1 (en) * 2003-02-18 2006-06-22 Maxcyte, Inc. Loading of cells with antigens by electroporation
US7745157B2 (en) * 2003-02-21 2010-06-29 University Of Maryland, Baltimore Human lymphocyte medium adjuvant
CA2517295C (en) 2003-02-27 2016-01-12 Northwest Biotherapeutics, Inc. Generation of dendritic cells from monocytic dendritic precursor cells with gm-csf in the absence of additional cytokines
EP1608728A2 (de) * 2003-03-31 2005-12-28 University Of South Florida Research Foundation, Inc. Materialien und verfahren zur regulation der ausbildung von fortsätzen in zellkultur
US20040203142A1 (en) * 2003-04-14 2004-10-14 Reliance Life Sciences Pvt. Ltd. Growth of neural precursor cells using umbilical cord blood serum and a process for the preparation thereof for therapeutic purposes
US20060182721A1 (en) * 2003-07-22 2006-08-17 Kirin Beer Kabshiki Kaisha Method of preparing langerhans cell from cd14-positive cell being human peripheral blood mononuclear cell with use of notch ligand delta-1, gm-csf and tgf-ss
JP2007507543A (ja) * 2003-10-06 2007-03-29 セダーズ−シナイ メディカル センター 樹状細胞治療によって誘導されるｔ細胞アネルギーを予防するためのｃｏｘ−２インヒビターの使用
WO2005043155A1 (en) * 2003-10-21 2005-05-12 Cedars-Sinai Medical Center System and method for the treatment of cancer, including cancers of the central nervous system
US20090227505A1 (en) * 2004-01-07 2009-09-10 Biotempt B.V. Methods and uses for protein breakdown products
EP1711206A2 (de) * 2004-01-26 2006-10-18 ChemoCentryx Inc Zusammensetzungen und verfahren zur verwendung von w-peptiden
US20070087986A1 (en) * 2004-01-26 2007-04-19 Brett Premack Compositions and methods for enhancing immunity by chemoattractant adjuvants
US20050214268A1 (en) * 2004-03-25 2005-09-29 Cavanagh William A Iii Methods for treating tumors and cancerous tissues
WO2005108554A1 (ja) * 2004-05-11 2005-11-17 Shukokai Incorporated 腫瘍ワクチンなどへの養子免疫細胞
JP2007537753A (ja) * 2004-05-17 2007-12-27 ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイ 抗原でパルスされた、二重特異性抗体（ＢｉＡｂ）でコーティングされた樹状細胞の使用
US7862829B2 (en) * 2004-07-09 2011-01-04 University Of North Carolina At Chapel Hill Viral adjuvants
CA2504451A1 (en) * 2004-08-10 2006-02-10 Geron Corporation Dendritic cell vaccines for treating cancer made from embryonic stem cells
US20060057121A1 (en) * 2004-09-10 2006-03-16 Demao Yang Compositions and treatments using ex vivo activated cells for myelosuppressed patients
EP1809737B9 (de) 2004-10-07 2011-10-05 Argos Therapeutics, Inc. Zusammensetzungen reifer dendritischer zellen und verfahren zu deren kultivierung
MX2007005866A (es) 2004-11-17 2007-11-12 Amgen Inc Anticuerpos monoclonales totalmente humanos para il-13.
WO2006079051A2 (en) * 2005-01-24 2006-07-27 University Of Rochester Methods of modifying cd11c+ dendritic cell development to form osteoclasts functional in the bone environment
WO2007046839A2 (en) * 2005-02-15 2007-04-26 University Of North Carolina At Chapel Hill New live virus vaccines
US20090263421A1 (en) * 2005-05-10 2009-10-22 Anna-Lena Spetz-Holmgren Cellular vaccine
US8668905B2 (en) * 2005-05-12 2014-03-11 University Of South Florida P53 vaccines for the treatment of cancers
CA2614084A1 (en) * 2005-07-05 2007-01-11 Biotempt B.V. Treatment of tumors
CN101336291A (zh) 2005-12-08 2008-12-31 西北生物治疗药物公司 用于诱导未成熟单核细胞的树突细胞的激活的组合物和方法
EP1864692A1 (de) 2006-06-07 2007-12-12 Biotempt B.V. Verwendung von peptiden zum Schutz von Strahlenschäden
WO2007137300A2 (en) 2006-05-23 2007-11-29 Bellicum Pharmaceuticals, Inc. Modified dendritic cells having enhanced survival and immunogenicity and related compositions and methods
CA2691346A1 (en) 2006-06-30 2008-01-10 Baylor Research Institute Dendritic cells generated using gm-csf and interferon alpha and loaded with heat-treated and killed cancer cells
US8129184B2 (en) 2006-09-26 2012-03-06 Cedars-Sinai Medical Center Cancer stem cell antigen vaccines and methods
WO2008039969A2 (en) 2006-09-28 2008-04-03 Cedars-Sinai Medical Center Cancer vaccines and vaccination methods
GB0622399D0 (en) * 2006-11-10 2006-12-20 Avaris Ab Novel compositions and uses thereof
US20080286315A1 (en) * 2007-01-31 2008-11-20 Penta Biotech, Inc. Methionine Enkephalin as an Adjuvant for Vaccine Immunizations
DE102007006736B4 (de) 2007-02-07 2012-01-12 Dagmar Briechle In-vitro Testkit zur tierversuchsfreien Bestimmung des sensibilisierenden Potentials einer Substanz
KR100887560B1 (ko) * 2007-04-24 2009-03-09 크레아젠 주식회사 준성숙 수지상 세포를 포함하는 류마티스 관절염 치료용약제학적 조성물
EP2173374A2 (de) * 2007-07-24 2010-04-14 Stichting Katholieke Universiteit, Radboud University Nijmegen Medical Centre Zusammensetzungen und verfahren zur erzeugung einer immunantwort in einer person
US8513208B2 (en) 2008-02-28 2013-08-20 Argos Therapeutics, Inc. Transient expression of immunomodulatory polypeptides for the prevention and treatment of autoimmune disease, allergy and transplant rejection
PL2328923T3 (pl) * 2008-09-02 2016-06-30 Cedars Sinai Medical Center Epitopy CD133
US8383768B2 (en) 2009-05-07 2013-02-26 Immunocellular Therapeutics, Ltd. CD133 epitopes
EP2281579A1 (de) 2009-08-05 2011-02-09 BioNTech AG Impfstoffzusammensetzung mit 5'-Cap-modifizierter RNA
JP5995247B2 (ja) * 2011-02-23 2016-09-21 国立大学法人京都大学 多能性幹細胞から樹状細胞を製造する方法
SG11201404570WA (en) * 2012-02-10 2014-11-27 Hakushinkouseikai Foundation Proliferating agent for monocyte, culture medium for proliferating monocyte, method for producing monocyte, method for producing dendritic cell, and method for producing dendritic cell vaccine
ES2662333T3 (es) 2013-02-14 2018-04-06 Immunocellular Therapeutics Ltd. Vacunas contra el cáncer y métodos de vacunación
JP6595469B2 (ja) * 2013-11-18 2019-10-23 ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション 自己免疫療法のための樹状細胞のマイクロスフェアベースの送達およびｅｘ ｖｉｖｏ操作
KR101807778B1 (ko) 2014-06-23 2018-01-18 제이더블유크레아젠 주식회사 특정 유전자 발현이 증가된 수지상세포의 제조방법 및 이를 이용하여 제조된 수지상세포를 포함하는 자가면역질환 치료 또는 예방용 조성물
WO2016185481A2 (en) 2015-05-20 2016-11-24 Yeda Research And Development Co. Ltd. Method of targeting senescent cells
US20170216354A1 (en) * 2015-06-12 2017-08-03 Batu Biologics, Inc. Clinically useful non-antigen pulsed dendritic cells
CN107849537A (zh) 2015-06-30 2018-03-27 西北生物治疗药物公司 诱发改善的或增加的抗肿瘤免疫应答的经最佳活化的树突细胞
RU2749610C2 (ru) 2015-09-15 2021-06-16 Нортвест Байотерапьютикс, Инк. Способы, относящиеся к композициям активированных дендритных клеток и к иммунотерапевтическому лечению индивидуумов с прогрессирующим раком
WO2017087763A1 (en) 2015-11-18 2017-05-26 Orbis Health Solutions Llc T7 alpha viral vector system
AU2017283480A1 (en) 2016-06-13 2019-01-24 Torque Therapeutics, Inc. Methods and compositions for promoting immune cell function
US11364264B2 (en) 2016-09-09 2022-06-21 The General Hospital Corporation Ex vivo antigen-presenting cells or activated CD-positive T cells for treatment of cancer
WO2018071576A1 (en) 2016-10-14 2018-04-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Treatment of tumors by inhibition of cd300f
WO2018213803A1 (en) 2017-05-19 2018-11-22 Neon Therapeutics, Inc. Immunogenic neoantigen identification
KR20210032924A (ko) 2017-09-05 2021-03-25 토크 테라퓨틱스, 인코포레이티드 치료용 단백질 조성물 및 그의 제조 및 사용 방법
SG11202004116QA (en) 2017-11-08 2020-06-29 Biontech Us Inc T cell manufacturing compositions and methods
EP3740237A4 (de) 2018-01-18 2021-10-20 University Of South Florida Tote antigenstimulierte unreife heterogene dendritische zellen als therapeutika für krankheiten
AU2019288277B2 (en) 2018-06-19 2025-10-30 H. Lee Moffitt Cancer Center And Research Institute, Inc. Oncolytic virus or antigen presenting cell mediated cancer therapy using type I interferon and CD40-ligand

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5130144B1 (en) * 1984-02-06 1995-08-15 Univ Johns Hopkins Human stem cells and monoclonal antibodies
US4861589A (en) * 1987-03-23 1989-08-29 Trustees Of Boston University Method for therapeutically treating abnormal cells expressing a major histocompatibility complex class II antigen using cytolytic inducer T4 cells
US20030072751A1 (en) * 1990-03-14 2003-04-17 Heribert Bohlen Idiotypic vaccination against b cell lymphoma
US5364783A (en) * 1990-05-14 1994-11-15 Massachusetts Institute Of Technology Retrovirus promoter-trap vectors
CA2084180A1 (en) * 1991-12-11 1993-06-12 Paul P. Hung Expression of specific immunogens using viral antigens
EP0563485A1 (de) * 1992-03-30 1993-10-06 Schering-Plough In-vitro-Erzeugung von menschlichen dendritischen Zellen
ATE260971T1 (de) * 1992-04-01 2004-03-15 Univ Rockefeller Verfahren zur in vitro kultivierung dendritischer vorläuferzellen und deren verwendung zur immunogen herstellung
WO1993020185A1 (en) * 1992-04-01 1993-10-14 Steinman Ralph M Method for in vitro proliferation of dendritic cell precursors and their use to produce immunogens
AU4678993A (en) * 1992-07-16 1994-02-14 Board Of Trustees Of The Leland Stanford Junior University Methods for using dendritic cells to activate t cells
US20020085993A1 (en) * 1992-11-25 2002-07-04 Ralph M. Steinman Method for in vitro proliferation of dendritic cell precursors and their use to produce immunogens
WO1995015340A1 (en) * 1993-12-03 1995-06-08 The Board Of Trustees Of Leland Stanford Junior University Monoclonal antibodies to antigens expressed by human dendritic cells
DE4412794A1 (de) * 1994-04-14 1995-12-14 Univ Ludwigs Albert Verfahren zur Herstellung von dendritischen Zellen, so erhaltene Zellen und Behälter zur Durchführung dieses Verfahrens
EP0765386B1 (de) * 1994-06-14 2014-12-10 The Board Of Trustees Of The Leland Stanford Junior University Methode zur in vivo aktivierung von t-zellen mit antigen inkubierten dendritischen zellen
US7659119B2 (en) * 1996-02-12 2010-02-09 Argos Therapeutics, Inc. Method and compositions for obtaining mature dendritic cells
ATE428769T1 (de) 1997-10-27 2009-05-15 Univ Rockefeller Methode und zusammensetzung zur herstellung von reifen dendritischen zellen

Also Published As

Publication number Publication date
CA2133409A1 (en) 1993-10-14
EP0633929A1 (de) 1995-01-18
JP2002507881A (ja) 2002-03-12
DE69333433D1 (de) 2004-04-08
US7923247B2 (en) 2011-04-12
CA2133409C (en) 2011-05-24
DE69333433T2 (de) 2004-12-02
US5851756A (en) 1998-12-22
DK0633929T3 (da) 2004-06-28
US20030134419A1 (en) 2003-07-17
US5994126A (en) 1999-11-30
JP3649335B2 (ja) 2005-05-18
US6475483B1 (en) 2002-11-05
ES2215991T3 (es) 2004-10-16
PT633929E (pt) 2004-07-30
US20090029469A1 (en) 2009-01-29
EP0633929B1 (de) 2004-03-03

Similar Documents

Publication Publication Date Title
ATE260971T1 (de) Verfahren zur in vitro kultivierung dendritischer vorläuferzellen und deren verwendung zur immunogen herstellung
JP3021379B2 (ja) ランゲルハンス細胞を含有する皮膚等価物
US5849589A (en) Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
ATE12255T1 (de) Verfahren zur herstellung von selbstreproduzierenden pankreatischen inseln aehnlichen strukturen von saeugetieren.
FI93310B (fi) Menetelmä rokotteen valmistamiseksi piluksia kantavien nisäkkään kudoksiin tarttuvien bakteerien aiheuttamia tauteja vastaan
DE69737023D1 (de) Methode zur behandlung von krebs und pathogenen infektionen unter verwendung von antigen-präsentierenden zellen beladen mit rna
ATE270323T1 (de) Zusammensetzungen und verfahren zur stimulierung der proliferation und der differenzierung von menschlichen fetalen und erwachsenen pankreatischen zellen ex vivo
ATE85080T1 (de) Menschlicher transformationswachstumsfaktor und vorlaeufer oder fragment hiervon, zellen, dna, vektoren und verfahren zu ihrer herstellung, zusammensetzungen und produkte, die diese enthalten, sowie davon abgeleitete antikoerper und diagnostizierverfahren.
DE69521794D1 (de) Zellen mit mehreren geänderten epitopen auf einem oberflächeantigen zur verwendung in transplantation
ATE192189T1 (de) In vitro bildung von dentritischen zellen
DE69334327D1 (de) Verfahren zur Herstellung sekretierter Proteine
IL98957A (en) Antigen-specific cytotoxic lymphocytes obtained by culture with IL-7 without stimulation by an antigen or mitogen
ATE246513T1 (de) Zubereitungen und verfahren für die behandlung von krebs und hyperproliferierenden krankheiten
DE69032922D1 (de) Menschliches intra-akrosomales spermaantigen zur verwendung in einem empfängnisverhütungsimpfstoff
ATE306252T1 (de) Verfahren zur herstellung kristalliner partikel zur inhalation
ATE517633T1 (de) Neues verfahren und zusammensetzung zur herstellung einer zellulären allogenen vakzine
DE4410136A1 (de) Tumorizide T-Lymphozyten
De Carvalho et al. Dendritic cells in different animal species: an overview
WO1998006823A3 (en) Cytokine-free culture of dendritic cells
KR101659158B1 (ko) 메트포민이 처리된 면역조절능을 갖는 간엽줄기세포 및 이를 포함하는 면역질환의 예방 또는 치료용 세포치료제 조성물
WO1991009935A1 (de) Matrix mit daran adhärent gebundenen zellen, sowie verfahren zur produktion von virus/virusantigen
JPS6445398A (en) Antithrombin-binding substance monoclonal antibody, hybridoma producing said antibody and method for purifying and measuring thrombin-binding substance utilizing said monoclonal antibody
KR850006705A (ko) 항파상풍항체 생산 인체-인체 하이브리도마의 제조방법
ATE322540T1 (de) Zubereitung für übertragung der aktive tumorspezifische immunisierung von einem immunisiertem allogenem knochenmarkspender
ATE127527T1 (de) Verfahren zur herstellung eines metastaseninhibitorenfaktors.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0633929

Country of ref document: EP